Clinical Trial Update: The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma [NA]

View source ↗

Summary

Ongoing clinical trial comparing TACE–lenvatinib with TACE–lenvatinib–ablation for intermediate recurrent hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Hepatocellular Carcinoma, Lenvatinib | NA | Status: RECRUITING